The impact of CYP2C19 genotype on phenoconversion by concomitant medication

被引:0
|
作者
De Jong, Laura [1 ]
Boussallami, Soukayna [1 ]
Hawinkels, Luuk [4 ]
Hoekstra, Menno [1 ]
Tushuizen, Maarten [4 ]
Rissmann, Robert [3 ]
Swen, Jesse [2 ]
Manson, Martijn [1 ]
机构
[1] Leiden Acad Ctr Drug Res, Div Syst Pharmacol & Pharm, Leiden, Netherlands
[2] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Leiden, Netherlands
[3] Leiden Univ, Ctr Human Drug Res, Med Ctr, Leiden, Netherlands
[4] Leiden Univ, Dept Gastroenterol Hepatol, Med Ctr, Leiden, Netherlands
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P0547
引用
收藏
页码:1326 / 1327
页数:2
相关论文
共 50 条
  • [41] Association between CYP2C19 genotype and proguanil oxidative polymorphism
    Coller, JK
    Somogyi, AA
    Bochner, F
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (06) : 659 - 660
  • [42] Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure
    Jin, Yuyan
    Pollock, Bruce G.
    Frank, Ellen
    Cassano, Giovanni B.
    Rucci, Paola
    Mueller, Daniel J.
    Kennedy, James L.
    Forgione, Rocco Nicola
    Kirshner, Margaret
    Kepple, Gail
    Fagiolini, Andrea
    Kupfer, David J.
    Bies, Robert R.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (01): : 62 - 72
  • [43] Development of a CYP2C19 Genotype Guided Dosing Algorithm for Voriconazole
    Mangal, Naveen
    Hamadeh, Issam
    Samant, Tanay
    Schmidt, Stephan
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S53 - S53
  • [44] Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients
    Katrijn Bogman
    Mariabeth Silkey
    Siew Pheng Chan
    Brian Tomlinson
    Cornelia Weber
    European Journal of Clinical Pharmacology, 2010, 66 : 1005 - 1015
  • [45] Dose optimization of omeprazole according to the CYP2C19 genotype.
    Park, So-Young
    Bae, Jung-Woo
    Choi, Chang-Ik
    PHARMACOTHERAPY, 2012, 32 (10): : E236 - E236
  • [46] Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients
    Bogman, Katrijn
    Silkey, Mariabeth
    Chan, Siew Pheng
    Tomlinson, Brian
    Weber, Cornelia
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (10) : 1005 - 1015
  • [47] Concordance between proguanil phenotype and CYP2C19 genotype in Chinese
    Hoskins, JM
    Shenfield, GM
    Gross, AS
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) : 611 - 614
  • [48] CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
    Roh, HK
    Dahl, ML
    Tybring, G
    Yamada, H
    Cha, YN
    Bertilsson, L
    PHARMACOGENETICS, 1996, 6 (06): : 547 - 551
  • [49] Disposition and effects of omeprazole are related to CYP2C19 genotype.
    Ohashi, K
    Furuta, T
    Kosuge, K
    Kimura, M
    Nishimoto, M
    Kaneko, E
    Ishizaki, T
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 152 - 152
  • [50] ALLELE AND GENOTYPE FREQUENCIES OF CYP2C19 IN CHINESE HAN POPULATION
    Yang Xiuchun
    Liu Fan
    Lu Jingchao
    Xiao Bing
    Cui Wei
    HEART, 2013, 99 : E128 - E128